Achillion Pharmaceuticals Inc (ACHN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Achillion Pharmaceuticals Inc (ACHN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH27007D
  • |
  • Pages: 58
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients with rare diseases. It is developing oral antiviral therapy for chronic hepatitis C (HCV) and a platform of potent and specific complement inhibitors. Achillion intends to develop and commercialize factor D inhibitors for rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD) and chronic obstructive pulmonary disease (COPD). Achillion is headquartered in New Haven, Connecticut, the US.

Achillion Pharmaceuticals Inc (ACHN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Achillion Pharma Enters into Licensing Agreement with Ora 11

Equity Offering 12

Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12

Achillion Pharma to Raise Funds through Secondary Offering of Shares 13

Achillion Pharma Raises USD225 Million in Private Placement of Shares 14

Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16

Achillion Pharma Completes Public Offering Of Shares For USD 142 Million 17

Achillion Pharma Completes Private Placement Of Shares For USD 42 Million 19

Achillion Pharmaceuticals Inc-Key Competitors 20

Achillion Pharmaceuticals Inc-Key Employees 21

Achillion Pharmaceuticals Inc-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Aug 08, 2018: Achillion reports second quarter 2018 financial results 23

May 02, 2018: Achillion Reports First Quarter 2018 Financial Results and Management Transition 25

Feb 22, 2018: Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results 27

Nov 01, 2017: Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs 29

Aug 08, 2017: Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor 30

May 04, 2017: Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs 33

Feb 23, 2017: Achillion Reports 2016 Fourth Quarter and Year-End Financial Results 35

Corporate Communications 37

Sep 10, 2018: Achillion Pharmaceuticals names Paul Firuta Chief Operating Officer 37

Aug 21, 2018: Achillion Pharmaceuticals names Dr. Steven Zelenkofske as Chief Medical Officer 38

Aug 15, 2018: Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer 39

Sep 11, 2017: Achillion Announces Strengthening of Management Team 40

Jul 10, 2017: Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change 41

Product News 42

09/11/2017: Janssen to Discontinue Hepatitis C Development Program 42

02/26/2018: Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy 43

Product Approvals 44

Nov 06, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 44

Clinical Trials 45

Jul 10, 2018: Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D 45

Dec 20, 2017: Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D 46

Dec 18, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study 47

Nov 14, 2017: Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G 48

Nov 01, 2017: Achillion Provides Update on ACH-4471 50

Nov 01, 2017: Achillion Provides Update on ACH-5228 52

Oct 23, 2017: Data on the clinical activity of simeprevir in combination with AL-335 and odalasvir (JNJ-4178) presented at the 2017 Liver Meeting 53

Apr 24, 2017: Update on the development of simeprevir as part of the triple combination with AL-335 and odalasvir (JNJ-4178) 54

Apr 22, 2017: Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 55

Apr 06, 2017: Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria 56

Apr 06, 2017: New data for simeprevir will be presented at EASL's International Liver Congress 2017 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58

List of Figures

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Achillion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Achillion Pharma Enters into Licensing Agreement with Ora 11

Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12

Achillion Pharma to Raise Funds through Secondary Offering of Shares 13

Achillion Pharma Raises USD225 Million in Private Placement of Shares 14

Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16

Achillion Pharma Completes Public Offering Of Shares For USD 142 Million 17

Achillion Pharma Completes Private Placement Of Shares For USD 42 Million 19

Achillion Pharmaceuticals Inc, Key Competitors 20

Achillion Pharmaceuticals Inc, Key Employees 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Achillion Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17805
Site License
USD 500 INR 35610
Corporate User License
USD 750 INR 53415

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com